Roger A Barker, Mart Saarma, Clive N Svendsen, Catherine Morgan, Alan Whone, Massimo S Fiandaca, Matthias Luz, Krystof S Bankiewicz, Brian Fiske, Lyndsey Isaacs, Arthur Roach, Thomas Phipps, Jeffrey H Kordower, Emma L Lane, Henri J Huttunen, Aideen Sullivan, Gerard O'Keeffe, Valeria Yartseva, Howard Federoff
{"title":"帕金森病的神经营养因子：现状、进展和遗留问题来自2023年研讨会的结论。","authors":"Roger A Barker, Mart Saarma, Clive N Svendsen, Catherine Morgan, Alan Whone, Massimo S Fiandaca, Matthias Luz, Krystof S Bankiewicz, Brian Fiske, Lyndsey Isaacs, Arthur Roach, Thomas Phipps, Jeffrey H Kordower, Emma L Lane, Henri J Huttunen, Aideen Sullivan, Gerard O'Keeffe, Valeria Yartseva, Howard Federoff","doi":"10.1177/1877718X241301041","DOIUrl":null,"url":null,"abstract":"<p><p>In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019.<sup>1</sup> This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial.<sup>2</sup> We then concluded with our recommendations on how GF studies in PD should develop going forward.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1659-1676"},"PeriodicalIF":4.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop.\",\"authors\":\"Roger A Barker, Mart Saarma, Clive N Svendsen, Catherine Morgan, Alan Whone, Massimo S Fiandaca, Matthias Luz, Krystof S Bankiewicz, Brian Fiske, Lyndsey Isaacs, Arthur Roach, Thomas Phipps, Jeffrey H Kordower, Emma L Lane, Henri J Huttunen, Aideen Sullivan, Gerard O'Keeffe, Valeria Yartseva, Howard Federoff\",\"doi\":\"10.1177/1877718X241301041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019.<sup>1</sup> This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial.<sup>2</sup> We then concluded with our recommendations on how GF studies in PD should develop going forward.</p>\",\"PeriodicalId\":16660,\"journal\":{\"name\":\"Journal of Parkinson's disease\",\"volume\":\"14 8\",\"pages\":\"1659-1676\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Parkinson's disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1877718X241301041\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Parkinson's disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1877718X241301041","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
2023年，英国慈善机构Cure Parkinson’s与Michael J Fox Parkinson’s研究基金会和Parkinson’s UK共同组织了一次研讨会，回顾帕金森病（PD）的生长因子（GFs）领域。这次2023年的研讨会回顾了在这4年中出现的新的相关数据，这些数据围绕着开发新的GFs和更好的研究模型，包括联合治疗的优点以及可以调节的治疗。我们还讨论了对已完成的GDNF试验（包括患者声音）以及最近完成的CDNF试验的分析中出现的GF递送和试验设计的新见解最后，我们提出了GF在PD研究中应该如何发展的建议。
Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop.
In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019.1 This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial.2 We then concluded with our recommendations on how GF studies in PD should develop going forward.
期刊介绍：
The Journal of Parkinson''s Disease (JPD) publishes original research in basic science, translational research and clinical medicine in Parkinson’s disease in cooperation with the Journal of Alzheimer''s Disease. It features a first class Editorial Board and provides rigorous peer review and rapid online publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
